October 24, 2025

Elinzanetant Approved for Menopausal Hot Flashes by FDA

Bayer’s dual neurokinin 1 and 3 receptor antagonist elinzanetant (Lynkuet) reduced the frequency and severity of menopausal vasomotor symptoms in phase 3 OASIS trials, providing a once daily, nonhormonal treatment option for moderate to severe hot flashes.

Conexiant

October 24, 2025

Zoonotic E coli Accounted for One-Fifth of UTI Cases

Genomic attribution estimates zoonotic share of community UTIs across Southern California.

Conexiant

October 24, 2025

A New Approach to Lowering Cardiovascular Risk?

Researchers evaluated obicetrapib’s effects on lipid levels and cardiovascular outcomes.

Conexiant

October 23, 2025

Waist Loss Only Part of Semaglutide’s Power

Semaglutide lowered cardiovascular events in patients with overweight or obesity without diabetes, independent of weight loss.

Conexiant

October 23, 2025

Can Sex Differences Really Explain Alzheimer’s Prevalence in Women?

Women account for most cases of Alzheimer’s globally, yet men show more age-related brain decline.

Conexiant

October 22, 2025

Fall Vaccines: What’s New, What’s Not

Updated CDC fall vaccine guidance simplifies covid, flu, and RSV shots with broad access and minimal changes from last year.

KFF Health News

October 22, 2025

FDA Redefining Depression Treatment with New Approvals?

Researchers analyze FDA-approved and Phase 3 antidepressants from 2009 to 2025.

Conexiant

October 22, 2025

Treating Female Hair Loss: What Are the Options?

Low-dose oral minoxidil showed comparable effectiveness to 5% topical minoxidil in treating female-pattern hair loss.

Conexiant

October 22, 2025

Do GLP-1RAs Differ in Cardiometabolic Protection?

Researchers found that liraglutide and semaglutide offer similar cardiovascular and kidney benefits in type 2 diabetes.

Conexiant